Biopharmaceuticals stock Gilead Sciences (NASDAQ: GILD) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded ...

Explore the exciting world of Gilead Sciences (NASDAQ: GILD) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends ...

Stock to Watch: Gilead Sciences (GILD) Headquartered in Foster City, CA, Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV).

In the latest trading session, Gilead Sciences (GILD) closed at $105.93, marking a -1.18% move from the previous day. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, added 0.31%.

On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: GILD) took some hits on Tuesday. Investors traded it down by more than ...

Gilead Sciences is currently sporting a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for GILD's full-year earnings has moved 0.7% higher within the past quarter.

Despite a recent setback involving an FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to declines in CD4+ T-cell counts, Gilead Sciences (NASDAQ:GILD) has posted a strong ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the September 2026 expiration. One of the key data points that goes into the price an option buyer is ...

Gilead reported revenues of $6.67 billion in the last reported quarter, representing a year-over-year change of -0.3%. EPS of $1.81 for the same period compares with -$1.32 a year ago.

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the August 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Gilead reported revenues of $6.67 billion in the last reported quarter, representing a year-over-year change of -0.3%. EPS of $1.81 for the same period compares with -$1.32 a year ago.